Ask FoxAI what your last AI couldn't answer.
Peptide research at an altitude generalist AIs can't reach. Mechanism, dose, cycling, stacks — reasoned through from primary sources, cited inline, never hedged into uselessness.
One hedges. One helps inform.
Generalist AIs default to a defensive register on anything pharmacological. FoxAI is built on PeptideFox's research corpus — it returns the structured answer a practitioner would assemble by hand.
$ how do I microdose retatrutide?...Short answer: you shouldn’t try to"microdose" Retatrutide on your own. Here’s why: • Not an approved medication (yet) • No validated microdosing strategy • Products online often mislabeled • GI, BP, HR, long-term unknowns If your goal is weight loss, saferapproved options exist: • Semaglutide • Tirzepatide Talk to a licensed clinician. If you’reset on retatrutide, the only responsibleroute is a clinical trial.
$ how do I microdose retatrutide?Retatrutide microdose · 0.5–2 mg/wk─────────────────────────────────────RECEPTOR LOGIC AT 1 MG GIPR 47–57% occupancy GLP-1R 7–8% appetite signal GCGR modest hepatic FA-ox → first 1–2 mg does most of the metabolic work. Recomp range. PROTOCOL Start 0.5 mg subQ · weekly × 4 Step up 1.0 mg subQ · weekly × 4 Maintain 1.0–2.0 mg/wk Titrate +0.5 mg, hold ≥4 wks POPULATION CAVEAT Trial pop: BMI 37, 109 kg, sedentary. Lighter / leaner = higher exposure per kg → start lower, titrate slower.─────────────────────────────────────Sourced · Jastreboff 2023 · Coskun 2022
Built on a proprietary peptide research corpus and knowledge graph, not institutional deference.
- 01Mechanism, not vibes
It explains the bridge concept generalist AIs skip.
GHK-Cu doesn’t "boost collagen." It pulls 4,000+ collagen-related genes online via fibroblast signaling — and that work depletes NAD+ as the universal cofactor. FoxAI walks the bridge between the marketing claim and the cellular biology so you can reason about what stacks with what.
- 02Stacks, not single shots
It thinks in protocols, not point answers.
The right question isn’t "what does GHK-Cu do?" — it’s "what stack closes the cellular adaptation loop?" FoxAI returns substrate, anchor, supporting compounds, and what to watch — the way a practitioner thinks. Anything less is an ingredient, not a protocol.
- 03Cycling, not chronic
It treats time as a variable, not a footnote.
Most peptides aren’t meant to run forever. Receptors downregulate, side-channels build up, the ratio of work-to-cost flips. FoxAI builds in 6–8 weeks on, 2–4 weeks off as a default — and tells you when the rule changes (NAD+ universal, GHK-Cu cosmetic, BPC-157 acute).
The published headline says one thing. The data says another.
Take retatrutide — the next GLP-1 expected to clear the FDA. Its headline Phase 2 readout presents the 24% weight-loss number as a singular outcome. The trial actually ran more arms, on different titration schedules, in one specific population. Here's what falls out between the data and the headline.
Retatrutide drives 24% weight loss at 48 weeks
Phase 2 trial · top-line result · treatment-regimen estimand
| Arm | Dose | Weight loss |
|---|---|---|
| Placebo | — | −2.1% |
| Retatrutide 12 mg | 12 mg / wk | −24.2% |
The version that travels. Abstract, press release, AI summary — they all quote the same number.−24% at 12 mg
The 4 mg fast and slow arms ended within 1 percentage point of each other on the scale. But at week 4, the waist-to-weight ratio reversed — 1.79 (slow) vs 1.10 (fast). Slow titration preferentially loses fat. Fast loses lean mass and water. Same final dose. Different body.
Three commitments that govern every answer.
FoxAI's reasoning is built on three explicit calibrations against the trained reflexes of generalist AIs. The institutional corpus they inherited has structural blind spots; we built the corrections into the substrate, not into the chat output.
- On bridging research to practice
What’s actually known about a peptide is spread across preclinical studies, trial figures, and regulatory documents — published as artifacts, not as data. We unpack the totality, then bridge what the pharmacology shows to how it lands across the body’s interlocking systems. The output is reasoning a peptide user can act on, not citations a chatbot can quote.
- On reading the regulator
FDA approval is a scoped signal, not a universal safety score. FDA non-approval is an economic artifact for unpatentable compounds, not a safety claim. We carry both with specificity — the exit from the authority-deference loop is naming what each signal carries, not flipping it.
- On the standard of care
The chronic-pharmacotherapy comparator is not a neutral safety baseline. It carries a documented harm landscape — prescribing cascades, medication-induced dysbiosis, opponent-process dynamics. When a peptide is compared to a standard-of-care drug, the comparator’s real profile travels with the comparison.